Dissection of inflammatory processes using chemokine biology: Lessons from clinical models

Immunology Letters

Volumn 145, Issue 1-2, 2012, Pages 55-61

  Nelson, Peter J ^a   Teixeira, Mauro M ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Animal models; Chemokines; Colitis; EAE; Kidney disease; Transplant rejection

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; BINDING PROTEIN; BL 5923; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCL25; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR1 ANTAGONIST; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CCR9; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR2 ANTAGONIST; CHEMOKINE RECEPTOR CXCR3; DF 2162; EVASIN 1; EVASIN 4; FRACTALKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; RS 504393; STEROID; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CARDIAC GRAFT REJECTION; COLITIS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE MODEL; EXPERIMENTAL MODEL; FIBROSING ALVEOLITIS; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; INFLAMMATION; KIDNEY FIBROSIS; LUNG FIBROSIS; LUPUS ERYTHEMATOSUS NEPHRITIS; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REPERFUSION INJURY; URETER OBSTRUCTION;

EID: 84862177053     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2012.04.011     Document Type: Review

References (95)

1. Bacon K., Baggiolini M., Broxmeyer H., Horuk R., Lindley I., Mantovani A., et al. Chemokine/chemokine receptor nomenclature. J Interferon Cytokine Res 2002, 22:1067-1068.
2. Murphy P.M. International union of pharmacology. XXX. Update on chemokine receptor nomenclature. Pharmacol Rev 2002, 54:227-229.
3. Russo R.C., Garcia C.C., Teixeira M.M. Anti-inflammatory drug development: broad or specific chemokine receptor antagonists. Curr Opin Drug Discov Dev 2010, 13:414-427.
4. Proudfoot A.E., Power C.A., Schwarz M.K. Anti-chemokine small molecule drugs: a promising future. Expert Opin Investig Drugs 2010, 19:345-355.
5. Pease J.E., Horuk R. Small molecule antagonists of chemokine receptors-is promiscuity a virtue. Curr Top Med Chem 2010, 10:1351-1358.
6. Deruaz M., Frauenschuh A., Alessandri A.L., Dias J.M., Coelho F.M., Russo R.C., et al. Ticks produce highly selective chemokine binding proteins with antiinflammatory activity. J Exp Med 2008, 205:2019-2031.
7. Russo R.C., Alessandri A.L., Garcia C.C., Cordeiro B.F., Pinho V., Cassali G.D., et al. Therapeutic effects of Evasin-1, a chemokine binding protein, in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2010.
8. Russo R.C., Guabiraba R., Garcia C.C., Barcelos L.S., Roffe E., Souza A.L., et al. Role of the chemokine receptor CXCR2 in bleomycin-induced pulmonary inflammation and fibrosis. Am J Respir Cell Mol Biol 2009, 40:410-421.
9. Jiang D., Liang J., Campanella G.S., Guo R., Yu S., Xie T., et al. Inhibition of pulmonary fibrosis in mice by CXCL10 requires glycosaminoglycan binding and syndecan-4. J Clin Invest 2010, 120:2049-2057.
10. + T-cell-mediated acute graft-versus-host disease responses. Blood 2005, 106:18-26.
11. + T cells during acute graft-versus-host disease. Leuk Lymphoma 2006, 47:1469-1476.
12. Castor M.G., Rezende B., Resende C.B., Alessandri A.L., Fagundes C.T., Sousa L.P., et al. The CCL3/macrophage inflammatory protein-1alpha-binding protein evasin-1 protects from graft-versus-host disease but does not modify graft-versus-leukemia in mice. J Immunol 2010, 184:2646-2654.
13. Andres P.G., Beck P.L., Mizoguchi E., Mizoguchi A., Bhan A.K., Dawson T., et al. Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sodium sulfate-mediated colitis: lack of CC chemokine receptor 5 expression results in a NK1.1+ lymphocyte-associated Th2-type immune response in the intestine. J Immunol 2000, 164:6303-6312.
14. Papadakis K.A. Chemokines in inflammatory bowel disease. Curr Allergy Asthma Rep 2004, 4:83-89.
15. Tokuyama H., Ueha S., Kurachi M., Matsushima K., Moriyasu F., Blumberg R.S., et al. The simultaneous blockade of chemokine receptors CCR2, CCR5 and CXCR3 by a non-peptide chemokine receptor antagonist protects mice from dextran sodium sulfate-mediated colitis. Int Immunol 2005, 17:1023-1034.
16. Kunkel E.J., Campbell D.J., Butcher E.C. Chemokines in lymphocyte trafficking and intestinal immunity. Microcirculation 2003, 10:313-323.
17. Lazarus N.H., Kunkel E.J., Johnston B., Wilson E., Youngman K.R., Butcher E.C. A common mucosal chemokine (mucosae-associated epithelial chemokine/CCL28) selectively attracts IgA plasmablasts. J Immunol 2003, 170:3799-3805.
18. Varona R., Cadenas V., Flores J., Martinez A.C., Marquez G. CCR6 has a non-redundant role in the development of inflammatory bowel disease. Eur J Immunol 2003, 33:2937-2946.
19. Teramoto K., Miura S., Tsuzuki Y., Hokari R., Watanabe C., Inamura T., et al. Increased lymphocyte trafficking to colonic microvessels is dependent on MAdCAM-1 and C-C chemokine mLARC/CCL20 in DSS-induced mice colitis. Clin Exp Immunol 2005, 139:421-428.
20. Williams I.R. Chemokine receptors and leukocyte trafficking in the mucosal immune system. Immunol Res 2004, 29:283-292.
21. Walters M.J., Wang Y., Lai N., Baumgart T., Zhao B.N., Dairaghi D.J., et al. Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J Pharmacol Exp Ther 2010, 335:61-69.
22. Eksteen B., Adams D.H. GSK-1605786, a selective small-molecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn's disease. IDrugs 2010, 13:472-781.
23. Umehara H., Bloom E.T., Okazaki T., Nagano Y., Yoshie O., Imai T. Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler Thromb Vasc Biol 2004, 24:34-40.
24. Nishimura M., Umehara H., Nakayama T., Yoneda O., Hieshima K., Kakizaki M., et al. Dual functions of fractalkine/CX3C ligand 1 in trafficking of perforin+/granzyme B+ cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J Immunol 2002, 168:6173-6180.
25. Niess J.H., Brand S., Gu X., Landsman L., Jung S., McCormick B.A., et al. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science 2005, 307:254-258.
26. + T cells in inflammatory bowel disease and their recruitment as intraepithelial lymphocytes. Inflamm Bowel Dis 2007, 13:837-846.
27. Vieira A.T., Fagundes C.T., Alessandri A.L., Castor M.G., Guabiraba R., Borges V.O., et al. Treatment with a novel chemokine-binding protein or eosinophil lineage-ablation protects mice from experimental colitis. Am J Pathol 2009, 175:2382-2391.
28. Ransohoff R.M., Bacon K.B. Chemokine receptor antagonism as a new therapy for multiple sclerosis. Expert Opin Investig Drugs 2000, 9:1079-1097.
29. Sorensen T.L., Tani M., Jensen J., Pierce V., Lucchinetti C., Folcik V.A., et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999, 103:807-815.
30. Trebst C., Sorensen T.L., Kivisakk P., Cathcart M.K., Hesselgesser J., Horuk R., et al. CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am J Pathol 2001, 159:1701-1710.
31. Balashov K.E., Rottman J.B., Weiner H.L., Hancock W.W. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci U S A 1999, 96:6873-6878.
32. Moreira M.A., Tilbery C.P., Monteiro L.P., Teixeira M.M., Teixeira A.L. Effect of the treatment with methylprednisolone on the cerebrospinal fluid and serum levels of CCL2 and CXCL10 chemokines in patients with active multiple sclerosis. Acta Neurol Scand 2006, 114:109-113.
33. Moreira M.A., Souza A.L., Lana-Peixoto M.A., Teixeira M.M., Teixeira A.L. Chemokines in the cerebrospinal fluid of patients with active and stable relapsing-remitting multiple sclerosis. Braz J Med Biol Res 2006, 39:441-445.
34. Izikson L., Klein R.S., Charo I.F., Weiner H.L., Luster A.D. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J Exp Med 2000, 192:1075-1080.
35. Manczak M., Jiang S., Orzechowska B., Adamus G. Crucial role of CCL3/MIP-1alpha in the recurrence of autoimmune anterior uveitis induced with myelin basic protein in Lewis rats. J Autoimmun 2002, 18:259-270.
36. Proudfoot A.E. Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol 2002, 2:106-115.
37. Tran E.H., Kuziel W.A., Owens T. Induction of experimental autoimmune encephalomyelitis in C57BL/6 mice deficient in either the chemokine macrophage inflammatory protein-1alpha or its CCR5 receptor. Eur J Immunol 2000, 30:1410-1415.
38. Schreiber K., Otura A.B., Ryder L.P., Madsen H.O., Jorgensen O.S., Svejgaard A., et al. Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRB1*1501, CCR5 deletion mutation, apolipoprotein E). Mult Scler 2002, 8:295-298.
39. Rottman J.B., Slavin A.J., Silva R., Weiner H.L., Gerard C.G., Hancock W.W. Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent. Eur J Immunol 2000, 30:2372-2377.
40. Liston A., Kohler R.E., Townley S., Haylock-Jacobs S., Comerford I., Caon A.C., et al. Inhibition of CCR6 function reduces the severity of experimental autoimmune encephalomyelitis via effects on the priming phase of the immune response. J Immunol 2009, 182:3121-3130.
41. Reboldi A., Coisne C., Baumjohann D., Benvenuto F., Bottinelli D., Lira S., et al. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol 2009, 10:514-523.
42. Carlson T., Kroenke M., Rao P., Lane T.E., Segal B. The Th17-ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune disease. J Exp Med 2008, 205:811-823.
43. Liu L., Darnall L., Hu T., Choi K., Lane T.E., Ransohoff R.M. Myelin repair is accelerated by inactivating CXCR2 on nonhematopoietic cells. J Neurosci 2010, 30:9074-9083.
44. Hewitson T.D. Renal tubulointerstitial fibrosis: common but never simple. Am J Physiol Renal Physiol 2009, 296:F1239-F1244.
45. Klahr S., Morrissey J. Obstructive nephropathy and renal fibrosis. Am J Physiol Renal Physiol 2002, 283:F861-F875.
46. Chevalier R.L., Forbes M.S., Thornhill B.A. Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int 2009, 75:1145-1152.
47. Anders H.J., Vielhauer V., Frink M., Linde Y., Cohen C.D., Blattner S.M., et al. A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J Clin Invest 2002, 109:251-259.
48. Eis V., Luckow B., Vielhauer V., Siveke J.T., Linde Y., Segerer S., et al. Chemokine receptor CCR1 but not CCR5 mediates leukocyte recruitment and subsequent renal fibrosis after unilateral ureteral obstruction. J Am Soc Nephrol 2004, 15:337-347.
49. Lee S.M., Graham A. Early immunopathologic events in experimental diabetic nephropathy: a study in db/db mice. Exp Mol Pathol 1980, 33:323-332.
50. Tesch G.H. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol 2008, 294:F697-F701.
51. Kang Y.S., Lee M.H., Song H.K., Ko G.J., Kwon O.S., Lim T.K., et al. CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice. Kidney Int 2010, 78:883-894.
52. Kulkarni O., Pawar R.D., Purschke W., Eulberg D., Selve N., Buchner K., et al. Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice. J Am Soc Nephrol 2007, 18:2350-2358.
53. Ninichuk V., Clauss S., Kulkarni O., Schmid H., Segerer S., Radomska E., et al. Late onset of Ccl2 blockade with the Spiegelmer mNOX-E36-3'PEG prevents glomerulosclerosis and improves glomerular filtration rate in db/db mice. Am J Pathol 2008, 172:628-637.
54. Ninichuk V., Khandoga A.G., Segerer S., Loetscher P., Schlapbach A., Revesz L., et al. The role of interstitial macrophages in nephropathy of type 2 diabetic db/db mice. Am J Pathol 2007, 170:1267-1276.
55. Bagavant H., Fu S.M. Pathogenesis of kidney disease in systemic lupus erythematosus. Curr Opin Rheumatol 2009, 21:489-494.
56. Davidson A., Aranow C. Lupus nephritis: lessons from murine models. Nat Rev Rheumatol 2010, 6:13-20.
57. Noris M., Bernasconi S., Casiraghi F., Sozzani S., Gotti E., Remuzzi G., et al. Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritis. Lab Invest 1995, 73:804-809.
58. Wada T., Furuichi K., Segawa-Takaeda C., Shimizu M., Sakai N., Takeda S.I., et al. MIP-1alpha and MCP-1 contribute to crescents and interstitial lesions in human crescentic glomerulonephritis. Kidney Int 1999, 56:995-1003.
59. Kim H.L., Lee D.S., Yang S.H., Lim C.S., Chung J.H., Kim S., et al. The polymorphism of monocyte chemoattractant protein-1 is associated with the renal disease of SLE. Am J Kidney Dis 2002, 40:1146-1152.
60. Perez de Lema G., Maier H., Franz T.J., Escribese M., Chilla S., Segerer S., et al. Chemokine receptor Ccr2 deficiency reduces renal disease and prolongs survival in MRL/lpr lupus-prone mice. J Am Soc Nephrol 2005, 16:3592-3601.
61. Balabanian K., Couderc J., Bouchet-Delbos L., Amara A., Berrebi D., Foussat A., et al. Role of the chemokine stromal cell-derived factor 1 in autoantibody production and nephritis in murine lupus. J Immunol 2003, 170:3392-3400.
62. Adalid-Peralta L., Mathian A., Tran T., Delbos L., Durand-Gasselin I., Berrebi D., et al. Leukocytes and the kidney contribute to interstitial inflammation in lupus nephritis. Kidney Int 2008, 73:172-180.
63. Schiffer L., Kumpers P., Davalos-Misslitz A.M., Haubitz M., Haller H., Anders H.J., et al. B-cell-attracting chemokine CXCL13 as a marker of disease activity and renal involvement in systemic lupus erythematosus (SLE). Nephrol Dial Transplant 2009, 24:3708-3712.
64. Lee H.T., Shiao Y.M., Wu T.H., Chen W.S., Hsu Y.H., Tsai S.F., et al. Serum BLC/CXCL13 concentrations and renal expression of CXCL13/CXCR5 in patients with systemic lupus erythematosus and lupus nephritis. J Rheumatol 2010, 37:45-52.
65. Moreth K., Brodbeck R., Babelova A., Gretz N., Spieker T., Zeng-Brouwers J., et al. The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritis. J Clin Invest 2010, 120:4251-4272.
66. Nelson P.J., Krensky A.M. Chemokines, chemokine receptors, and allograft rejection. Immunity 2001, 14:377-386.
67. Cugini D., Azzollini N., Gagliardini E., Cassis P., Bertini R., Colotta F., et al. Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion. Kidney Int 2005, 67:1753-1761.
68. Bertini R., Allegretti M., Bizzarri C., Moriconi A., Locati M., Zampella G., et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A 2004, 101:11791-11796.
69. El-Sawy T., Belperio J.A., Strieter R.M., Remick D.G., Fairchild R.L. Inhibition of polymorphonuclear leukocyte-mediated graft damage synergizes with short-term costimulatory blockade to prevent cardiac allograft rejection. Circulation 2005, 112:320-331.
70. Morita K., Miura M., Paolone D.R., Engeman T.M., Kapoor A., Remick D.G., et al. Early chemokine cascades in murine cardiac grafts regulate T cell recruitment and progression of acute allograft rejection. J Immunol 2001, 167:2979-2984.
71. Belperio J.A., Keane M.P., Burdick M.D., Gomperts B.N., Xue Y.Y., Hong K., et al. CXCR2/CXCR2 ligand biology during lung transplant ischemia-reperfusion injury. J Immunol 2005, 175:6931-6939.
72. Bedke J., Nelson P.J., Kiss E., Muenchmeier N., Rek A., Behnes C.L., et al. A novel CXCL8 protein-based antagonist in acute experimental renal allograft damage. Mol Immunol 2010, 47:1047-1057.
73. Furuichi K., Gao J.L., Murphy P.M. Chemokine receptor CX3CR1 regulates renal interstitial fibrosis after ischemia-reperfusion injury. Am J Pathol 2006, 169:372-387.
74. Grone H.J., Weber C., Weber K.S., Grone E.F., Rabelink T., Klier C.M., et al. Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment. FASEB J 1999, 13:1371-1383.
75. Song E., Zou H., Yao Y., Proudfoot A., Antus B., Liu S., et al. Early application of Met-RANTES ameliorates chronic allograft nephropathy. Kidney Int 2002, 61:676-685.
76. Murphy P.M., Baggiolini M., Charo I.F., Hebert C.A., Horuk R., Matsushima K., et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000, 52:145-176.
77. Weber C., Weber K.S., Klier C., Gu S., Wank R., Horuk R., et al. Specialized roles of the chemokine receptors CCR1 and CCR5 in the recruitment of monocytes and T(H)1-like/CD45RO(+) T cells. Blood 2001, 97:1144-1146.
78. Gao W., Topham P.S., King J.A., Smiley S.T., Csizmadia V., Lu B., et al. Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection. J Clin Invest 2000, 105:35-44.
79. Horuk R., Clayberger C., Krensky A.M., Wang Z., Grone H.J., Weber C., et al. A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection. J Biol Chem 2001, 276:4199-4204.
80. Horuk R., Shurey S., Ng H.P., May K., Bauman J.G., Islam I., et al. CCR1-specific non-peptide antagonist: efficacy in a rabbit allograft rejection model. Immunol Lett 2001, 76:193-201.
81. Bedke J., Kiss E., Schaefer L., Behnes C.L., Bonrouhi M., Gretz N., et al. Beneficial effects of CCR1 blockade on the progression of chronic renal allograft damage. Am J Transplant 2007, 7:527-537.
82. Fischereder M., Luckow B., Hocher B., Wuthrich R.P., Rothenpieler U., Schneeberger H., et al. CC chemokine receptor 5 and renal-transplant survival. Lancet 2001, 357:1758-1761.
83. Gao W., Faia K.L., Csizmadia V., Smiley S.T., Soler D., King J.A., et al. Beneficial effects of targeting CCR5 in allograft recipients. Transplantation 2001, 72:1199-1205.
84. Luckow B., Joergensen J., Chilla S., Li J.P., Henger A., Kiss E., et al. Reduced intragraft mRNA expression of matrix metalloproteinases Mmp3, Mmp12, Mmp13 and Adam8, and diminished transplant arteriosclerosis in Ccr5-deficient mice. Eur J Immunol 2004, 34:2568-2578.
85. Dehmel S., Wang S., Schmidt C., Kiss E., Loewe R.P., Chilla S., et al. Chemokine receptor Ccr5 deficiency induces alternative macrophage activation and improves long-term renal allograft outcome. Eur J Immunol 2010, 40:267-278.
86. Hancock W.W., Gao W., Faia K.L., Csizmadia V. Chemokines and their receptors in allograft rejection. Curr Opin Immunol 2000, 12:511-516.
87. Hancock W.W., Gao W., Csizmadia V., Faia K.L., Shemmeri N., Luster A.D. Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med 2001, 193:975-980.
88. Halloran P.F., Fairchild R.L. The puzzling role of CXCR3 and its ligands in organ allograft rejection. Am J Transplant 2008, 8:1578-1579.
89. Zerwes H.G., Li J., Kovarik J., Streiff M., Hofmann M., Roth L., et al. The chemokine receptor Cxcr3 is not essential for acute cardiac allograft rejection in mice and rats. Am J Transplant 2008, 8:1604-1613.
90. Kwun J., Hazinedaroglu S.M., Schadde E., Kayaoglu H.A., Fechner J., Hu H.Z., et al. Unaltered graft survival and intragraft lymphocytes infiltration in the cardiac allograft of Cxcr3-/- mouse recipients. Am J Transplant 2008, 8:1593-1603.
91. Hancock W.W., Wang L., Ye Q., Han R., Lee I. Chemokines and their receptors as markers of allograft rejection and targets for immunosuppression. Curr Opin Immunol 2003, 15:479-486.
92. Hopken U.E., Droese J., Li J.P., Joergensen J., Breitfeld D., Zerwes H.G., et al. The chemokine receptor CCR7 controls lymph node-dependent cytotoxic T cell priming in alloimmune responses. Eur J Immunol 2004, 34:461-470.
93. Beckmann J.H., Yan S., Luhrs H., Heid B., Skubich S., Forster R., et al. Prolongation of allograft survival in ccr7-deficient mice. Transplantation 2004, 77:1809-1814.
94. Liu X., Mishra P., Yu S., Beckmann J., Wendland M., Kocks J., et al. Tolerance induction towards cardiac allografts under costimulation blockade is impaired in CCR7-deficient animals but can be restored by adoptive transfer of syngeneic plasmacytoid dendritic cells. Eur J Immunol 2011, 41:611-623.
95. Gregson A.L., Hoji A., Palchevskiy V., Hu S., Weigt S.S., Liao E., et al. Protection against bronchiolitis obliterans syndrome is associated with allograft CCR7+ CD45RA- T regulatory cells. PLoS One 2010, 5:e11354.